{"name":"Oncternal Therapeutics, Inc","slug":"oncternal-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Zilovertamab Phase 3 readout (Lymphoma, Mantle-Cell, Lymphoma)","drug":"Zilovertamab","drugSlug":"zilovertamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-24","label":"Zilovertamab Phase 2 readout (DLBCL, Diffuse Large B-Cell Lymphoma)","drug":"Zilovertamab","drugSlug":"zilovertamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-03-29","label":"Zilovertamab Phase 3 readout (Diffuse Large B-Cell Lymphoma)","drug":"Zilovertamab","drugSlug":"zilovertamab","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Zilovertamab","genericName":"Zilovertamab","slug":"zilovertamab","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Zilovertamab","genericName":"Zilovertamab","slug":"zilovertamab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQWFhFT2RROUMwS0doQ2tWSmJjN1Rjb2ZHTG1wSkpfTUx5SlJqeDBfRjE4TmdkVEJfM1pYUmo0c2hkbmlkVWRMUkQ3M3ZjblBBb0RpN0hDOXdJaUxOUG5SLWdvbGtsVkJhUjFHRmo0SHhFeFItUU5TclFOVHJ3N2lyUm5oMnF1a25qX0QzdzhmMFNxMVY3b1hlbUJlTFlzUExCbzZENnllUHROTUFyY2RZWlRB?oc=5","date":"2025-08-25","type":"pipeline","source":"Fierce Biotech","summary":"Cell therapy biotech Appia shuts down as funding runs dry - Fierce Biotech","headline":"Cell therapy biotech Appia shuts down as funding runs dry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNlBZRHB4V2NDZExTTzNORlhvaVNBWDVYOGtXMUxNNEduX3JyRUhBTHkzZG1BMkRWSnh3SjBMSnc5NWNXOTBEUWVoRFVZcWpNcmoxOExSVC1hNDNONXktSVMySm9mN3Z2TWx2M0o1TnZKQjNoNXZWZ01ZQnQ5WGpoWjYtLW13VU9CMjdIS29TV0Rxeno0N09kbkpkdGVNRkxkTU11MkF3?oc=5","date":"2025-07-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Oncternal sells assets for up to $68m and calls it quits - Pharmaceutical Technology","headline":"Oncternal sells assets for up to $68m and calls it quits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQQnNLQk11MnpiY0NRdE1KMjQ0SmhCSUhVNEYzbkFhbGlnZTJUTWFJYjZtN244TGUwUWd2VTNjRmNUNHVTT2YwOEVlN3Nud1VxdXhnOEpuaWp1WU11TTZJaVBTU29KeDFud09ZNnZuSUdWMmFRc2J6NTZvSW5kVTZ6dHpXNTM2NkpwRGhHalpWTmM1RmtSTnVvZlVQTUVrU3p4ellzWEFIQ1ZucVc0NjFxVkdWRVIwMHp4SzhF?oc=5","date":"2025-05-13","type":"pipeline","source":"BioSpace","summary":"Sonoma Biotherapeutics Appoints Rajesh Krishnan, Ph.D., as Chief Technical Officer - BioSpace","headline":"Sonoma Biotherapeutics Appoints Rajesh Krishnan, Ph.D., as Chief Technical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOVGljZEU3N0ZpYlZLOXJtZVRXNjBSRFFUdzFqVVV1eTBMN3BSYmRZaU9kM19WMlJVeWtYMHc2WWZWS3M1Y3p0UFVNT2ZReFRWeWlMcnpqU29MV0VNUTZmc3ZzZEJkX1BkaHJjOXhKQ19hcUFlU00wOWFyNlJUV3lYUlJXdjliRWRUZ2F2V2lR?oc=5","date":"2025-04-10","type":"pipeline","source":"citybiz","summary":"Alpha Cognition Appoints Robert Wills To Board - citybiz","headline":"Alpha Cognition Appoints Robert Wills To Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxOckZzaHdFVzFVM042X3VQNC1OWGFKZHJTejZweE5SU2I3MndnaV9vSTJ2WEYyVkNQOG9CNllESzlRcEhveDlZaW5LclFQYmpkSWsxaVN1N2NtR1hmV3F4eVJXMUpFUHVnSDJaZ2NMVVMzZm13YXhMczU2dlZBMGQ4V2hEeHVhZE41d25ycklhekJCVDZLM2tadFdYOGlsVnEwczFQYW9iNFNzTmVidTBtek1HYjlJcWFZY3FCa2x5WjhUeFpFMzdhVGxDQXdKSkdrSlV1WU4zVE9pelFUcFFHbHc4NjBVQU1KOFBoOHVxM3JEYjhqYS05dTdocVRCcmNUcTd3?oc=5","date":"2025-03-07","type":"pipeline","source":"GlobeNewswire","summary":"Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewswire","headline":"Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQTEhLeEFQWmhvYzBURUJTbEZkSGxjeTRuU0hvUlhKQ2VTWnJBcVJCbGpCR3dfeElueC1NTldkT1ZSNHd0bkZJR0dJZW5tMjVfdC1iNmEybnFubkk3d0pOUEFEcm9jTmVQT2VPaFVqdXpFY1NxMnFrQUhtNVNBSHNkRHcwMFJSbUJrdENPS2N4bnZaalhfSkxrMUFBajFoZnNl?oc=5","date":"2024-11-25","type":"pipeline","source":"Investing.com","summary":"Oncternal shares to be delisted from Nasdaq - Investing.com","headline":"Oncternal shares to be delisted from Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxORGo5LUwzT0twX2Z4SVJwdFdtUWI3ZU13Mi1qZXlSdFZqaWZwblhYeVlyeHI1b25NWkdFNHZGQlBYdV9Ga1U4Wm93X1YxVkFZWm9uZ0dUUnVPbDVkdEFIWGdZUk5aajlOR21YRDlpV2VxbUNUUlRVNVQxRXQxa1RxTXFIN3plejViLWkzLVhaSmRYSjc0RG9DYUl4RDZQM3l1dzVnOEFfalVabG9rNmhGMGM2cE0?oc=5","date":"2024-09-12","type":"trial","source":"Fierce Biotech","summary":"Oncternal folds all clinical trials after lackluster data drop, patient death - Fierce Biotech","headline":"Oncternal folds all clinical trials after lackluster data drop, patient death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBEcjE0RllYMk9KQVJrbXpHeWZILXJfRzh2WUlwLVNadzhHeDA5ek1mYmVDV1J0M1REeFd3VGtHbEhxNE15UlVCekFNNS1oRlBXNEpvZXp6OXc0bEtfcTVlaXBIUmpUSnIwN19wMw?oc=5","date":"2021-06-17","type":"trial","source":"Wiley Online Library","summary":"TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL - Wiley Online Library","headline":"TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNRXZtTnVDN2tiWGI1U1B3a3gxRGlidGJuOXNBS1JCRUpoQW5fWWVRcnhvU1Z3SWtGN0xkY2pzQXhKOFg3NERoYjFwRnhzUWhRT1hiRGY1Q2pSUHg0cnNDSnc0TFJ2RUU2TWR6d214dmlaa1VyTmNzbWZsaDZTSnVpYUR5LW9samh1MGp2ci1xSWlkOGd6Y3hJY2pNN3M?oc=5","date":"2021-04-12","type":"pipeline","source":"Yahoo Finance","summary":"Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel - Yahoo Finance","headline":"Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFBQTUJMN3JHSmlXWGJSQndnRDVSUkFENmdRZ2FIZlVUSFNqTVR4NXltYWJvbDJ2TVg0MDJkZmhCVzFBSlowcHJkVDVvekdTdw?oc=5","date":"2020-11-07","type":"pipeline","source":"Stock Titan","summary":"Latest ONCT News - Oncternal Therapeutics Announces the Sale o... - Stock Titan","headline":"Latest ONCT News - Oncternal Therapeutics Announces the Sale o...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQLVk1MmZpYmRka2F4YVJKSHhBSDVVUzE2M2ZBVmxHWExheEdUU09RUUo5UDFwMGMzeWx3VVQxVGtST2hBSnFocTdKNzRMck92V09ST1BpUTRXZTJpdFFGdE5pZTlhNWVLTDZCSE1JZ0FDSnpxUWo5dldmYUxxMGZBMlc4U1lHd3o0?oc=5","date":"2019-03-08","type":"deal","source":"Pharmaceutical Technology","summary":"Oncternal Therapeutics signs definitive merger agreement with GTx - Pharmaceutical Technology","headline":"Oncternal Therapeutics signs definitive merger agreement with GTx","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQT0ZBcVdjSG1sQURlLVRoODA4enFyS1pSS0x3czBvYXFnTG12RFJhRUpiLUlCNGlhZWFXblQ0bzFWUUttVHFhVXNZSlZSYmJWcS1kUmRqbzRhTDR0UnNVazd0c0N0QVRpNUhGejJJVW0wR2tTN25iR1hGRnlaZzFfSTMtRmtjTV8zTm8ySFZfQjU0QUZ6bkh3TVV2QnZBenBDcl9KSHlIZmNCRkZuRDhkZmpIWXZ1R1Fmc01JNVdaaUxPalRzZFk0YjhZTUk0NXdtREFJd01qc2pLYjgyYlZj?oc=5","date":"2018-04-03","type":"pipeline","source":"prnewswire.com","summary":"Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors - prnewswire.com","headline":"Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}